Processa Pharmaceuticals News Today

Next generation capecitabine led to positive preliminary efficacy results in patients with stage III or IV gastrointestinal tract cancer.

Processa Pharmaceuticals, Inc. (NASDAQ:PCSA – Get Free Report) was the recipient of a large decline in short interest in May. As of May 15th, there was short interest totalling 47,500 shares, a decline of 91.6% from the April 30th total of 568,300 shares. Based on an average daily volume of 1,410,000 shares, the days-to-cover ratio […]

HC Wainwright reaffirmed their buy rating on shares of Processa Pharmaceuticals (NASDAQ:PCSA – Free Report) in a report published on Monday morning, Benzinga reports. HC Wainwright currently has a $8.00 price objective on the stock. HC Wainwright also issued estimates for Processa Pharmaceuticals’ Q2 2024 earnings at ($0.98) EPS, Q3 2024 earnings at ($1.02) EPS, […]

HC Wainwright reaffirmed their buy rating on shares of Processa Pharmaceuticals (NASDAQ:PCSA – Free Report) in a report published on Monday, Benzinga reports. HC Wainwright currently has a $8.00 target price on the stock. HC Wainwright also issued estimates for Processa Pharmaceuticals’ Q2 2024 earnings at ($0.98) EPS, Q3 2024 earnings at ($1.02) EPS, FY2024 […]

Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) and Processa Pharmaceuticals (NASDAQ:PCSA – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk. Profitability This table compares Enliven Therapeutics and […]

Brings extensive experience in all phases of oncology drug developmentHANOVER, Md., April 30, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals,...

/PRNewswire/ -- DelveInsights Gastroparesis Market Insights report includes a comprehensive understanding of current treatment practices, gastroparesis...

Insiders who bought US$210.6k worth of Processa Pharmaceuticals, Inc. ( NASDAQ:PCSA ) stock in the last year recovered...

HANOVER, MD, Feb. 14, 2024 -- Processa Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy...